Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
Total Valuation
Avadel Pharmaceuticals has a market cap or net worth of $956.75M. The enterprise value is $487.31M.
Market Cap$956.75M
Enterprise Value$487.31M
Share Statistics
Avadel Pharmaceuticals has 96,738,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96,738,940
Owned by Insiders0.93%
Owned by Institutions36.85%
Financial Efficiency
Avadel Pharmaceuticals’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -36.19%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-36.19%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee899.56K
Profits Per Employee-259.74K
Employee Count188
Asset Turnover1.03
Inventory Turnover0.75
Valuation Ratios
The current PE Ratio of Avadel Pharmaceuticals is -20.48. Avadel Pharmaceuticals’s PEG ratio is -0.04.
PE Ratio-20.48
PS Ratio0.00
PB Ratio-20.35
Price to Fair Value13.54
Price to FCF-6.06
Price to Operating Cash Flow-6.12
PEG Ratio-0.04
Income Statement
In the last 12 months, Avadel Pharmaceuticals had revenue of 169.12M and earned -48.83M in profits. Earnings per share was -0.51.
Revenue169.12M
Gross Profit153.84M
Operating Income-42.40M
Pretax Income-49.08M
Net Income-48.83M
EBITDA-35.57M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -25.24M and capital expenditures 0.00, giving a free cash flow of -25.43M billion.
Operating Cash Flow-25.24M
Free Cash Flow-25.43M
Free Cash Flow per Share-0.26
Dividends & Yields
Avadel Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change-40.92%
50-Day Moving Average8.69
200-Day Moving Average10.36
Relative Strength Index (RSI)50.99
Average Volume (3m)1.29M
Important Dates
Avadel Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Avadel Pharmaceuticals as a current ratio of 2.75, with Debt / Equity ratio of -619.64%
Current Ratio2.75
Quick Ratio2.33
Debt to Market Cap<0.01
Net Debt to EBITDA1.40
Interest Coverage Ratio-3.91
Taxes
In the past 12 months, Avadel Pharmaceuticals has paid -247.00K in taxes.
Income Tax-247.00K
Effective Tax Rate<0.01
Enterprise Valuation
Avadel Pharmaceuticals EV to EBITDA ratio is -26.72, with an EV/FCF ratio of -20.26.
EV to Sales5.62
EV to EBITDA-26.72
EV to Free Cash Flow-20.26
EV to Operating Cash Flow-20.26
Balance Sheet
Avadel Pharmaceuticals has $66.48M in cash and marketable securities with $2.90M in debt, giving a net cash position of -$63.59M billion.
Cash & Marketable Securities$66.48M
Total Debt$2.90M
Net Cash-$63.59M
Net Cash Per Share-$0.66
Tangible Book Value Per Share$0.60
Margins
Gross margin is 0.00%, with operating margin of -25.07%, and net profit margin of -28.87%.
Gross Margin0.00%
Operating Margin-25.07%
Pretax Margin-29.02%
Net Profit Margin-28.87%
EBITDA Margin-21.03%
EBIT Margin-22.62%
Analyst Forecast
The average price target for Avadel Pharmaceuticals is $18.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$18.00
Price Target Upside92.72% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast252.64%
EPS Growth Forecast85.10%